Safety of RG2077 in Patients With Multiple Sclerosis

Completed · Phase 1

Conditions studied: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

In brief

Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS. Study hypothesis: RG2077 will arrest MS if administered early in the course of MS and decrease accumulation of lesions on MRI.

Key facts

Study ID

NCT00076934

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

20

Starts

2003-01-01

Expected to finish

2006-02-01

Last updated by the study team

2017-03-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions
• Have declined all FDA approved therapies for MS

Where it is running

• Brigham and Women's Hospital/Harvard Medical School — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.